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ABSTRACT
Introduction: Current international guidelines for
cardiac rehabilitation (CR) advocate moderate-intensity
exercise training (MISS, moderate-intensity steady
state). This recommendation predates significant
advances in medical therapy for coronary heart disease
(CHD) and may not be the most appropriate strategy
for the ‘modern’ patient with CHD. High-intensity
interval training (HIIT) appears to be a safe and
effective alternative, resulting in greater improvements
in peak oxygen uptake (VO2 peak). To date, HIIT trials
have predominantly been proof-of-concept studies in
the laboratory setting and conducted outside the UK.
The purpose of this multicentre randomised controlled
trial is to compare the effects of HIIT and MISS
training in patients with CHD attending UK CR
programmes.
Methods and analysis: This pragmatic study will
randomly allocate 510 patients with CHD to 8 weeks of
twice weekly HIIT or MISS training at 3 centres in the
UK. HIIT will consist of 10 high-intensity (85–90%
peak power output (PPO)) and 10 low-intensity
(20–25% PPO) intervals, each lasting 1 min. MISS
training will follow usual care recommendations,
adhering to currently accepted UK guidelines
(ie, >20 min continuous exercise at 40–70% heart rate
reserve). Outcome measures will be assessed at
baseline, 8 weeks and 12 months. The primary
outcome for the trial will be change in VO2 peak as
determined by maximal cardiopulmonary exercise
testing. Secondary measures will assess physiological,
psychosocial and economic outcomes.
Ethics and dissemination: The study protocol
V.1.0, dated 1 February 2016, was approved by the
NHS Health Research Authority, East Midlands—
Leicester South Research Ethics Committee (16/EM/
0079). Recruitment will start in August 2016 and will
be completed in June 2018. Results will be published
in peer-reviewed journals, presented at national and
international scientific meetings and are expected to
inform future national guidelines for exercise training in
UK CR.
Trial registration number: NCT02784873;
pre-results.
INTRODUCTION
Coronary heart disease (CHD) accounts for
one-third of all deaths globally, totalling 7.4
million in 2013.1 In the UK alone, ∼175 000
myocardial infarctions (MI) are recorded
annually.2 While this is a signiﬁcant number,
advances in preventative therapy and
medical treatment have contributed to an
overall reduction in CHD mortality in the
UK.3 An estimated 2.3 million people are
now living with the disease,2 and with a
Strengths and limitations of this study
▪ To ensure the findings are applicable to the ‘real
world’, this study will adopt a pragmatic, multi-
centre approach to assessing the efficacy of
high-intensity interval training (HIIT) in UK
cardiac rehabilitation (CR) programmes.
▪ This study will conduct an holistic, multidiscip-
linary investigation into the physiological, psy-
chosocial and economic value of HIIT in patients
with CHD.
▪ As a limitation, participants will only attend
supervised exercise twice weekly for 8 weeks.
This is suboptimal in relation to published data
recommending three times per week for
12 weeks.
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growing population of CHD survivors, the need for com-
prehensive and cost-effective chronic disease manage-
ment is ever more apparent.
Integral to the long-term management of CHD is the
provision of cardiovascular rehabilitation (CR) pro-
grammes.4 5 Exercise training is considered a key com-
ponent alongside risk factor management and
facilitation of long-term behavioural change.4
Compelling evidence exists for CR programmes, with
meta-analyses historically highlighting a favourable effect
on functional capacity, health-related quality of life
(HR-QoL), hospital admissions and mortality.6–8 The
most recent data, however, do not conﬁrm a survival
beneﬁt from participation in CR.9 This may relate to the
ability of contemporary medical care, interventional car-
diology and secondary prevention pharmacotherapy, to
achieve much of what was previously attributed to CR.
However, CR does improve HR-QoL and, as such, strat-
egies to maximise long-term physical functioning (ie,
optimised, personalised exercise training programmes)
should be pursued in patients with CHD. Tangible bene-
ﬁts are realistic for the individual and an overburdened
healthcare system, and CR programmes have a vital role
to play in this regard.
In addition to improved medical care, the prescribed
intensity of the exercise training interventions included
in the recent meta-analysis by Anderson et al9 may help
explain the lack of improvement in mortality rates with
CR. Exercise intensity ranged from 50% to 95% of peak
oxygen uptake (VO2 peak), with the vast majority of pro-
tocols at the lower end of this range, that is, equivalent
to moderate-intensity exercise (∼46–64% VO2 peak).10
This is in line with current international exercise guide-
lines for CHD which advocate moderate-intensity train-
ing (<80% VO2 peak) prescribed as either interval or
steady state (MISS, moderate-intensity steady state).10 It
is well known that greater improvements in VO2 peak can
be expected with exercise training of a higher intensity
and that a higher VO2 peak is associated with an improve-
ment in mortality risk.11 12 Given that current guidelines
predate signiﬁcant advances in interventional cardiology
and medical therapy, moderate-intensity exercise may be
considered conservative and suboptimal for the
‘modern’ patient with CHD.13 Greater beneﬁt may be
attained by participating in high-intensity interval train-
ing (HIIT) involving repeated bursts of harder exercise
interspersed with periods of recovery.14 15 High intensity,
in this context, describes exercise performed above
moderate intensity (ie, >64% VO2 peak) as opposed to
the maximal or supramaximal exercise speciﬁed in
some protocols in healthy individuals.16
Meta-analyses have indicated the superiority
(∼1.7 mL/kg/min) of HIIT over MISS for improvements
in VO2 peak in patients with CHD.
14 15 17 These analyses,
however, are limited by small sample sizes and the sig-
niﬁcant heterogeneity of study populations and HIIT
protocols. HIIT protocols can be modiﬁed in numerous
ways (eg, modality, intensity, interval duration) to suit
the population or intended outcome,18 but there is no
consensus as to the optimal conﬁguration for the CHD
population.17 In a landmark European study, high-
intensity intervals lasting 4 min were deemed unfeasible
in patients with CHD and offered no additional beneﬁt
over continuous training.19 As an alternative, low-volume
HIIT uses 1 min intervals to provide intermittent meta-
bolic stimulus with non-sustained cardiovascular stress.
This appears to be safe and well tolerated in addition to
being effective at improving VO2 peak in patients with
CHD.20 21 The beneﬁt of this ‘low-volume HIIT’
approach in ‘real world’ CR programmes in the UK,
however, cannot be conﬁrmed. Previous studies have gen-
erally been proof-of-concept studies conducted under
‘laboratory’ conditions. Carefully selected populations,
tightly controlled exercise protocols and researcher-led
interventions may limit the ecological validity of such
studies. Likewise, substantial international variation in the
provision and implementation of exercise-based CR may
reduce the extent to which non-UK data can be applied
to CR programmes in the UK.
The high-intensity interval training versus moderate-
intensity steady-state training in UK Cardiac
Rehabilitation trial (HIIT or MISS UK) is a pragmatic
multicentre randomised controlled trial and economic
evaluation comparing two CR exercise interventions.
The primary objectives of the trial are:
1. To assess the effect of HIIT on VO2 peak and cardio-
vascular health.
2. To assess the acceptability of HIIT and the psycho-
logical and motivational factors associated with com-
pliance and adherence.
3. To assess the effect of HIIT on lifestyle physical activ-
ity and a HR-QoL.
4. To conduct an economic evaluation of HIIT com-
pared with MISS in CR programmes in the UK.
5. To assess the safety of HIIT.
In patients attending CR programmes in the UK, we
hypothesise that HIIT will improve VO2 peak to a greater
extent than MISS training. In this population, data relat-
ing to the effects of HIIT (particularly low-volume
HIIT) on clinical, physiological, psychosocial and eco-
nomic outcomes are limited but appear to indicate at
least an equivalent effect.22–24 As such, we also hypothe-
sise that HIIT will (1) be more acceptable than MISS
and demonstrate greater patient compliance and adher-
ence; (2) improve cardiovascular health to a greater
extent than MISS; (3) improve HR-QoL to a greater
extent than MISS; (4) lead to more positive motivation
and attitudes to exercise than MISS; (5) increase short-
term and medium-term participation in lifestyle physical
activity to a greater extent than MISS; (6) be a cost-
effective alternative to MISS and (7) be as safe as MISS.
METHODS AND ANALYSIS
The HIIT or MISS UK study is a pragmatic, single-blind,
multicentre, longitudinal, randomised controlled trial
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and economic evaluation. In line with the median UK
CR programme duration of 8.5 weeks,25 participants will
be randomly allocated to 8 weeks of HIIT or MISS train-
ing (usual care). Outcomes will be measured at baseline,
8 weeks and 12 months by assessors blinded to group
allocation. Study interventions will be delivered by clin-
ical (not research) staff. The study is pragmatic in
nature in that it will be conducted in existing CR pro-
grammes. It is, therefore, accepted that some variation
in the delivery of usual care will be evident between
study sites. This will ensure generalisability of the ﬁnd-
ings to UK CR programmes. The trial protocol adheres
to the Standard Protocol Items: Recommendations for
Clinical Trials (SPIRIT) guidelines.26
Setting
The HIIT or MISS study will be conducted at three com-
munity CR centres; (1) Atrium Health, Centre for
Exercise & Health, Coventry, (2) Department of Sport,
Health & Exercise Science, University of Hull and Hull
Royal Inﬁrmary, Kingston-upon-Hull and (3) Ystrad Fawr
Hospital, Ystrad Mynach, South Wales. Programmes are
commissioned by University Hospitals Coventry &
Warwickshire NHS Trust, City Healthcare Partnership
CIC (Hull) and Aneurin Bevan University Health Board
(South Wales), respectively. Starting August 2016, 510
CR patients will be recruited over a 2-year period.
Participants
The study will recruit patients with established coronary
artery disease (CAD) referred for CR exercise training.
Patients with MI, coronary artery bypass graft (CABG)
surgery, angiographically documented CAD and elective
percutaneous coronary intervention (PCI) will be
eligible.
General inclusion criteria
1. Successfully revascularised following PCI or CABG.
2. Angiographically documented non-obstructive CAD.
3. Left ventricular ejection fraction >40%.
4. Clinically stable (symptoms and medication) for
>2 weeks.
5. 18–75-year of age.
General exclusion criteria
1. Symptoms of ischaemia.
2. Signiﬁcant left main stem stenosis.
3. NYHA class III–IV symptoms.
4. Compromising ventricular arrhythmia.
5. Signiﬁcant valvular heart disease.
6. Inability to comply with guidelines for participation
in exercise testing and training.27–29
7. Signiﬁcant limiting comorbidities that would prevent
full participation.
Additional exclusion criteria
Further to the analysis of cardiopulmonary exercise test
(CPET) and resting echocardiography by the research
team at baseline, and prior to randomisation, patients
will be prevented from continuing their involvement in
the study if there is indication of:
1. Exercise-induced ischaemia or signiﬁcant haemo-
dynamic compromise.
2. Left ventricular ejection fraction <40%.
3. Clinical instability in accordance with CR guidelines.27 29
4. Inability to comply with guidelines for participation
in exercise testing and training.28 29
Study procedures
An outline of the participant pathway for the study is
presented in ﬁgure 1. Eligibility will be assessed by the
research team at each site under the supervision of the
local principal investigator (PI). Potential participants
will be approached at their ﬁrst outpatient CR appoint-
ment by a member of the study team: verbal and written
information will be provided. A subsequent phone call
(at least 48 hours later) will conﬁrm those who wish to
participate. Informed consent will be attained at the
baseline assessment visit, which will coincide with an out-
patient CR appointment. Baseline procedures will
include CPET, echocardiogram, venipuncture, arterial
oscillometry and clinical examination. Instruments to
assess HR-QoL, health and social care use and the psy-
chological and motivational factors associated with com-
pliance and adherence will be administered, and a
lifestyle physical activity monitor will be ﬁtted (removed
1 week later). Further to the analysis of CPET and echo-
cardiography at baseline, the local research team will
rescreen potential participants for eligibility. Those who
are ineligible will take no further part in the study but
will continue with usual care CR. Eligible participants
will subsequently be randomised to 8 weeks of twice
weekly HIIT or MISS training. All measures completed
at baseline will be repeated at 8 weeks and 12 months.
Interventions
The study will compare HIIT with current usual care in
the UK—that is, moderate-intensity interval training pro-
gressing towards moderate-intensity steady-state (MISS)
training.29 Table 1 provides a summary of both interven-
tions, and table 2 details the framework within which
the HIIT intervention will be progressed. Participants
will attend twice weekly CR exercise sessions for 8 weeks,
performing either HIIT or MISS training for the cardio-
vascular component of their programme. In accordance
with current UK standards,29 a muscular strength and
endurance training programme will also be completed
by both study groups, and participation in additional
home-based exercise recommended as standard.
Participants who are unable/unwilling to comply with
the HIIT protocol will be permitted to cease involve-
ment in the HIIT intervention and continue with usual
care CR (not as part of the trial). Where two or more
consecutive training sessions are missed, the interven-
tion period can be extended to 10 weeks. As is common-
place for CR programmes in the UK, there will be some
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variation in the structure and delivery of the MISS inter-
vention at each of the study sites. This is in keeping with
the pragmatic nature of the trial. Each centre will,
however, adhere to current UK standards.29
The following exercise training criteria must be satisﬁed
for participants to be regarded as having sufﬁciently
adhered to the treatment protocol:
▸ A minimum of 80% of sessions completed (13 of 16).
▸ HIIT—10×1 min protocol achieved by week 4.
▸ MISS—20 min continuous CV exercise achieved by
week 4.
The number of participants who do not meet the
above criteria will be recorded.
Randomisation and blinding
Trial participants will be randomised to HIIT or MISS
on a 1:1 basis. The random allocation sequence will be
generated by the trial statistician using a random
number generator and implemented by a central
telephone registration and randomisation service at
Warwick Clinical Trials Unit. Randomisation will be
stratiﬁed by site using random permuted blocks random-
isation within each site to ensure approximately equal
numbers of patients are allocated to HIIT and MISS. To
ensure allocation concealment, researchers will request
randomisation on completion of all baseline assess-
ments. Outcome assessors will be blinded to group allo-
cation, as will the trial statistician. Clinical staff
delivering the interventions cannot be blinded, however,
they will not be involved in data analysis or reporting.
Study outcome measures
The primary outcome measure is the change in peak
oxygen uptake (VO2 peak) at 8 weeks. A number of sec-
ondary outcome measures will also be assessed, namely
(1) acceptability and the motivational and attitudinal
factors associated with compliance and adherence; (2)
HR-QoL; (3) service and resource use; (4) lifestyle
Figure 1 Study flow chart.
4 McGregor G, et al. BMJ Open 2016;6:e012843. doi:10.1136/bmjopen-2016-012843
Open Access
physical activity; (5) cardiovascular reserve; (6) cardiac
remodelling; (7) arterial remodelling; (8) cardiovascular
health and (9) safety. Table 3 provides the complete
schedule for outcome assessment.
Cardiopulmonary exercise testing will be performed
to measure VO2 peak and other parameters representa-
tive of cardiovascular reserve. Tests will be conducted
using a standard bicycle ramp protocol in accordance
with American Thoracic Society guideline.30 Participants
will be encouraged to maintain a cadence of 70 rpm
until symptom-limited volitional fatigue prevents con-
tinuation. Criteria for the assessment of a good partici-
pant effort will include peak respiratory exchange ratio
(RER) >1.10, peak HR≥85% predicted and RPE ≥18.31
Compliance and adherence will be determined by
recording the number of training sessions attended and
successfully completed in accordance with the exercise
protocol. Drop-out from the programme will also be
documented for both study groups in addition to reason
for drop-out, where provided voluntarily by participants.
To assess the psychological and motivational factors asso-
ciated with compliance and adherence to the exercise
training interventions, the predictive effects of self-
efﬁcacy, motivation, need satisfaction and implicit and
explicit attitudes and, reciprocally, the effects of training
on self-efﬁcacy, motivation, need satisfaction and implicit
and explicit attitudes, will be quantitatively measured
using validated tools: (1) the Multidimensional
Self-Efﬁcacy for Exercise Scale (MSES);32 (2) the
Behavioural Regulation in Exercise Questionnaire-2
(BREQ-2);33 (3) the Psychological Need Satisfaction in
Exercise Scale (PNSES);32 (4) Courneya and Bobick’s
7-point Bipolar Adjectival Rating Scale34 and (5) a
Single-Category Implicit Association Test (SC-IAT).35
Semistructured interviews will qualitatively evaluate
acceptability in a subgroup of 40 patients, representative
of completers and drop-outs in both intervention
groups. Verbatim transcripts will be thematically
analysed.36
Health-related quality of life will be assessed with the
ﬁve-item EuroQoL (EQ-5D-5L),37 as recommended by
the National Institute for Health and Care Excellence in
the UK for economic evaluation in clinical trials.38
General population preference-based tariffs for the UK
Table 1 Comparison of HIIT and MISS training interventions
HIIT MISS
▸ Exercise sessions conducted as follows:
1. Warm up: 15 min total, 10 min <40% HRR, 5 min <70%
HRR.
2. Cardiovascular component: exercise cycle ergometer
interval training (Wattbike Trainer; Wattbike, Nottingham,
UK):high=85–90% PPO from CPET, low=20–25% PPO
(exercise intensity will not to be prescribed from gas
exchange data, ie, %VO2 peak). Change in intensity from
low to high achieved by altering cadence (rpm). Exercise
HR will not exceed HRmax from CPET.
3. Cool down: 10 min, <40% HRR.
▸ Duration of intervals and total programme duration
increased within a standardised framework (table 2).
▸ Workload increased bi-weekly in response to participant
reported RPE (only after the full 10×1 protocol has been
achieved). If RPE <17 during the last two high-intensity
intervals, then workload will be increased.
▸ Exercise sessions conducted in accordance with BACPR/
ACPICR standards,29 adhering to the following key
principles:
1. Warm up: 15 min, <40% HRR.
2. Cardiovascular component: moderate-intensity interval
training progressing towards 20–40 min continuous
cardiovascular exercise at 40–70% HRR (from CPET)
and RPE 12–14.
3. Cool down: 10 min, <40% HRR.
▸ Initial duration based on participant’s previous and current
PA levels and CPET performance.
▸ Duration and workload of cardiovascular component
adjusted, as tolerated, within the above parameters, in
response to exercising HR, participant reported RPE and
symptoms. As per current practice, priority will be given to
increasing duration until 20 min of continuous exercise has
been achieved. Thereafter, workload can be increased in
conjunction with duration.
CPET, cardiopulmonary exercise test; HIIT, high-intensity interval training; HR, heart rate; HRR, heart rate reserve; MISS, moderate-intensity
steady state; PA, physical activity; PPO, peak power output; RPE, rating of perceived exertion; VO2 peak, peak oxygen uptake.
Table 2 Breakdown of HIIT training programme by week
Week
High-intensity intervals
(number×time in min)
Low-intensity intervals
(number×time in min)
Total high-intensity
exercise (min)
Total low-intensity
exercise (min)
Total
exercise time
(min)
1 5×0.5 5×1 2.5 5 7.5
2 5×1 5×1 5 5 10
3 7×1 7×1 7 7 14
4–8 10×1 10×1 10 10 20
HIIT, high-intensity interval training.
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allow for the comparison of EQ-5D index scores with
population norms and other health conditions.39 An
adapted client service receipt inventory (CSRI), based
on examples in the DIRUM database,40 will be adminis-
tered at each time point to capture participant health
and social care service use since the last time point
(plus a retrospective 2-month period at baseline).
Lifestyle physical activity will be recorded over a 7-day
period with an ActiGraph GT9X Link (Actigraph,
Pensacola, Florida, USA) worn on the wrist.
Comprehensive evaluation of participants’ daily physical
activity patterns will be derived from the unit’s 3-axis
accelerometer, magnetometer and gyroscope. The
Actigraph GT9X Link is considered the gold standard in
non-invasive research grade physical activity monitoring
and has been extensively validated.
To quantify cardiac remodelling, echocardiographic
images will be obtained and analysed as recommended
in current guidelines.41 42 To assess cardiac structure
and function (systolic and diastolic), standard techni-
ques will be used including 2D, M-mode, pulse wave
Doppler and tissue Doppler echocardiography. To inves-
tigate arterial remodelling, pulse wave velocity will be
determined through the non-invasive method of bra-
chial oscillometry (Mobil-O-Graph PWA Monitor, IEM
GmbH, Stolberg, Germany). A blood pressure cuff will
be placed on the participant’s upper left arm and will
inﬂate and deﬂate automatically. Mobil-O-Graph PWA
has been validated against internationally recognised
invasive and non-invasive gold standards.43
Standard clinical examination will include medical
history, stature, body mass and cardiovascular risk factor
assessment, that is, resting blood pressure, diabetes,
family history of premature CHD and smoking status.
Blood sampling will be performed to allow the measure-
ment of biomarkers of cardiovascular and metabolic
health. Routine testing will include full blood cell count,
liver function, urea and electrolytes, glycaemic control
and a full lipid proﬁle. Serum and plasma will be stored
for the analysis of current and emerging biochemical
markers of cardiovascular and metabolic health relating
to inﬂammation, cardiac remodelling, pro-thrombosis,
endocrine function and lipids.44 45
To verify the safety of HIIT and MISS training per-
formed in CR, adverse and serious adverse events will be
carefully monitored, recorded and reported. In line with
the principles of Good Clinical Practice, the nature and
severity of the event, in addition to its potential associ-
ation with the exercise training intervention, will be
ascertained by the local PI and ratiﬁed by the trial
clinician.46
Sample size
Given the pragmatic nature of the trial, a 1.5 mL/kg/min
larger improvement of VO2 peak in the HIIT group
compared to the MISS group is considered a clinically
relevant difference. Keteyian and colleagues reported
a reduction of ∼15% in all-cause mortality for each
1 mL/kg/min increase in VO2 peak in a large CR cohort
with revascularised coronary disease.47 In the present
study, a sample size of 191 patients in each group will be
sufﬁcient to detect this difference assuming a SD of
4.5 mL/kg/min, a power of 90% and a signiﬁcance level
of 5%. The assumed SD is based on observations from
Conraads et al.19 This trial is similar to HIIT or MISS and
reported a loss to follow-up from baseline to post-
Table 3 Outcome measures and assessment schedule
Measure Instrument Assessment time point
Primary outcome
VO2 peak CPET Baseline, 8 weeks, 12 months
Secondary outcomes
Compliance, adherence Compliance/adherence/drop-out rates Continuous
MSES Baseline, 8 weeks, 12 months
BREQ-2 Baseline, 8 weeks, 12 months
PNSES Baseline, 8 weeks, 12 months
Bipolar adjectival rating scale Baseline, 8 weeks, 12 months
SC-IAT Baseline, 8 weeks, 12 months
Acceptability Semistructured interviews 8 weeks
HR-QOL EQ-5D Baseline, 8 weeks, 12 months
Service and resource use CSRI Baseline, 8 weeks, 12 months
Lifestyle physical activity Physical activity monitor Baseline, 8 weeks, 12 months
Cardiovascular reserve CPET Baseline, 8 weeks, 12 months
Cardiac remodelling Echocardiography Baseline, 8 weeks, 12 months
Arterial remodelling Arterial oscillometry Baseline, 8 weeks, 12 months
Cardiovascular health Clinical examination Baseline, 8 weeks, 12 months
Blood sampling Baseline, 8 weeks, 12 months
Safety Adverse event monitoring Continuous
BREQ-2, Behavioural Regulation in Exercise Questionnaire-2; CPET, cardiopulmonary exercise test; CSRI, client service receipt inventory;
EQ-5D, 5 item EuroQol; HR-QoL, health-related quality of life; MSES, Multidimensional Self-Efficacy for Exercise Scale; PNSES,
Psychological Need Satisfaction in Exercise Scale; SC-IAT, Single-Category Implicit Association Test; VO2 peak, peak oxygen uptake.
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intervention of 13%. A conservative drop-out of ∼25%
yields a required sample size of 510 patients (255 per
group) to be randomised. Should the drop-out rate at
12 months be 50%, then the study would retain power of
76% to detect a difference of 1.5 mL/kg/min in the
primary outcome at this time point using the aforemen-
tioned assumptions.
Data collection and management
Study data will be collected on a case report form by the
research team at baseline, 8 weeks and 12 months. Each
participant will be allocated a unique study ID number;
a list of participants will be stored electronically by
UHCW NHS Trust. Data will be anonymously entered
into REDCap (Research Electronic Data Capture),48 a
secure, web-based application designed to support data
capture for research studies. This will be hosted by
Cardiff Metropolitan University.
Statistical analysis
The primary end point for the statistical analysis is the
mean change in VO2 peak (mL/kg/min) from baseline
to 8 weeks of follow-up. The primary end point will be
compared between intervention arms using a general
linear model with the treatment group and baseline
VO2 peak ﬁtted as covariates, and 8-week VO2 peak as the
dependant variable. The linear model will be adjusted
for the continuous covariate age, and the categorical
covariates sex and study site. Further adjustment vari-
ables may be investigated as part of the exploratory ana-
lysis. The robustness of the primary outcome analysis will
be investigated using three standard multiple imputation
methods (monotone regression, fully conditional speciﬁ-
cation regression and Markov chain Monte Carlo
(MCMC)).
The secondary outcome measures will be analysed
using the same covariates as the primary outcome ana-
lysis. Likewise, the differences between groups in terms
of continuous secondary outcome measures will be
assessed with the same statistical model as the primary
outcome analysis. Differences between treatment arms
for binary, unordered categorical and ordinal secondary
outcome variables will be analysed using logistic regres-
sion, multinomial logistic regression and proportional
odds models, respectively.
The primary and secondary outcome analyses will be
conducted at the conventional (two-sided) 5% level. To
reduce the risk of false-positive claims, all secondary ana-
lyses will be considered to be exploratory if a non-
signiﬁcant result is obtained from the primary analysis
and, whenever reported, the failure to achieve a signiﬁ-
cant result in the primary analysis will be declared. It is
not proposed to formally adjust for multiple testing
among the secondary end points as these are likely to be
correlated so that standard adjustment techniques such
as the Bonferroni method would be conservative. All
analyses will be performed on an intention-to-treat basis.
A per protocol analysis will be conducted as an exploratory
analysis, as will subgroup analyses (for subgroups prespe-
ciﬁed in the protocol) and repeated measures mixed
models.
All data will be summarised and reported in accord-
ance with the Consolidated Standards of Reporting
Trials (CONSORT) guideline.49 No formal interim ana-
lyses are anticipated.
Economic evaluation
In line with the National Institute for Health and
Clinical Excellence (NICE) guidance on the economic
evaluation of public health interventions,50 from a soci-
etal perspective, a cost-consequence analysis of HIIT
(embedded within CR) compared with MISS training
(representing usual care) will be undertaken. Within the
cost-consequence analysis, there will be an embedded
cost-utility analysis, using Quality Adjusted Life Years
(QALYs) gained with HR-QoL weights drawn from
EQ-5D-5L. This approach has been chosen because
QALYs allow comparison with the value for money of
other medical and public health interventions but do
not capture the full range of relevant outcomes in
public health prevention.50 We will use STATA V.14 to
bootstrap (5000 replications) the differences in cost and
outcomes, to produce a 95% CI, cost-effectiveness
planes and cost-effectiveness acceptability curves, to
present to healthcare policymakers and local commis-
sioners the probability that the intervention is cost-
effective at different payer thresholds.
The health economics component of the study will be
written up in accordance with the Consolidated Health
Economic Evaluation Reporting Standards (CHEERS)
statement for the reporting of published economic
evaluations.51
Patient and public involvement
Patient and public involvement has been integral to
protocol development. A formal consultation event was
attended by a representative sample of current CR parti-
cipants in August 2015. Participants were introduced to
various different approaches to exercise training and
asked to comment on their suitability. A range of opi-
nions and views were recorded with the overriding senti-
ment being that participants would be prepared to
engage in HIIT with minimal concern. Close supervision
by experienced CR exercise professionals was considered
essential. The only signiﬁcant negative comment related
to the fact that HIIT would be performed solely on an
exercise bike as opposed to a range of cardiovascular
exercise equipment. However, participants conﬁrmed
that they would be prepared to tolerate this in the short
term. Two CR participants will sit on the trial steering
group for the duration of the trial.
Dissemination and impact
Throughout the trial, media outlets (including social
media) will be informed of progress, and the experi-
ences gained will be presented at national conferences
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and non-academic outlets such as national governing
body publications. On completion, the study results will
be published in peer-reviewed journals and presented at
scientiﬁc meetings. The results will also be disseminated
in newsletter form throughout the UK via national gov-
erning bodies and at local research and patient confer-
ence events. It is anticipated that the results of the study
will inform future national guidelines for exercise train-
ing in UK CR.
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